Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT05905783 is registered in ClinicalTrials.gov with ACELYRIN Inc. as lead sponsor.

NCT NCT05905783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05905783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
ACELYRIN Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 22, 2023
Completion date
January 27, 2025
Enrollment
258 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa